Brief: Aptinyx Reports Results From Phase 2 Study Of Nyx-458 In Cognitive Impairment And Provides Pipeline And Corporate Update

Aptinyx

27/02/2023 21:49

Feb 27 (Reuters) - Aptinyx Inc  APTX.O :
    * APTINYX REPORTS RESULTS FROM PHASE 2 STUDY OF NYX-458 IN
COGNITIVE IMPAIRMENT ASSOCIATED WITH PARKINSON'S DISEASE AND
DEMENTIA WITH LEWY BODIES AND PROVIDES PIPELINE AND CORPORATE
UPDATE
    * APTINYX INC - COMPANY WILL UNDERTAKE COST-CUTTING MEASURES
AND
EXPLORE STRATEGIC ALTERNATIVES
    * APTINYX INC - WILL TERMINATE ITS ONGOING STUDY OF NYX-783
IN
PTSD AND ANALYZE DATA AVAILABLE TO DATE
    * APTINYX INC - NYX-458 DID NOT DEMONSTRATE SUFFICIENT
EFFICACY IN
PHASE 2 STUDY TO SUPPORT FURTHER DEVELOPMENT BY APTINYX

Source text for Eikon:  ID:nBw7NqFc9a 
Further company coverage:  APTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))